ArticleJournal for immunotherapy of cancer2022

Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia.

Matthew G Cyr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.